The Melbourne-based pharmaceutical company, Medicines Development for Global Health (MDGH), is planning clinical trials to assess moxidectin as a new treatment for scabies. The scabies parasite disproportionately affects indigenous Australian communities, as well as poorer populations and tropical areas around the world.
MDGH focuses on developing treatments for neglected tropical diseases. The company has already developed the drug moxidectin as the first new treatment in 30 years for onchocerciasis, sometimes referred to as river blindness. In 2018 the US Food and Drug Administration awarded the company a priority voucher for moxidectin and approved the drug for the treatment of onchocerciasis.